Lipid-lowering therapy at hospital discharge after coronary artery bypass grafting

American Journal of Health-System Pharmacy

Volumn 59, Issue 6, 2002, Pages 548-551

  Khanderia, Ujjaini ^a   Faulkner, Tracy V ^a   Townsend, Kevin A ^a   Streetman, Daniel S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; COLESTIPOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NICOTINIC ACID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0037086143     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.6.548     Document Type: Article

References (28)

1. The cholesterol facts: A summary of the evidence relating to dietary fats, serum cholesterol, and coronary heart disease
2. Pravastatin prevents clinical events in revascularized patients with average concentrations
3. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
4. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation
5. Therapeutic efficacy of the lipid-lowering armamentarium: The clinical benefits of aggressive lipid-lowering therapy
6. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
8. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
9. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
11. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting
12. Coronary artery bypass graft disease
13. Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention
14. Relation of saphenous vein graft obstruction to serum cholesterol levels
15. Aortocoronary bypass saphenous vein atherosclerosis: Anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months postoperatively
16. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: A study 10 years after aortocoronary bypass surgery
17. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
18. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
19. Beneficial effects of colestipolniacin on coronary atherosclerosis. A 4-year follow-up
20. Inadequate measurement of hyperlipidemia after coronary bypass surgery shown by medical audit
21. ACC/AHA guidelines for coronary artery bypass graft surgery
22. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality
23. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
24. Inaccuracy of serum lipid measurements after open heart operations
25. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results